Floatz logo

vx-970

Extrapulmonary Small Cell Cancer

National Cancer Institute (NCI)Phase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Extrapulmonary Small Cell Cancer cohort.

Asset / SponsorPhaseRating
Hycamtin
National Cancer Institute (NCI)
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
EpicentRx, Inc.
Phase 2BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB
Vinorelbine
EpicentRx, Inc.
Phase 2BB
Lurbinectedin
SystImmune Inc.
Phase 3BB

View all 31 →

Same molecule, other indications

vx-970 is also rated in:

small cell lung carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
fallopian tube carcinomaDormant
B
Indicative ·
60 / 100
View asset →
ovarian carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →